Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of a fixed dose of Azilect® (1 mg/day) vs placebo as assessed by the
change from baseline in mean total daily OFF time during 18 weeks of treatment in
levodopa-treated Parkinson's Disease (PD) patients with motor fluctuations in Korea.